GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] we use "appetite suppression" to describe three different mechanisms — 12 comments in the full submission. View in context.
437
c/glp1science·submitted 10 days ago by u/nurse_ish_2025

[Discussion] we use "appetite suppression" to describe three different mechanisms

Discussionbranch of 6 comments

Genuinely asking, not being difficult. Everyone in c/meta repeats that incretin is important. I believe it, but I have never seen anyone show why, and when I search I get 4 threads of people agreeing with each other. Is there a paper? Is there a measurement? Or is this one of those things that is true because it has…

Read the full submission and all 12 comments →

This branch

6 comments, started 10 days ago
u/enzo_danquah13 points·10 days ago

The evidence standard in c/vendorvetting gets called too strict about once a month, and every time, the thread ends with the complainant agreeing.

replysharereportpermalink
u/formulary_fighterappeals10 points·9 days ago

incretin physiology is mechanism, the mechanism layer

replysharereportpermalink
u/nurse_ish_2025OP6 points·9 days ago

The half-life is 16 hours, which means week 16 is genuinely still ramp-up. Week 24 is steady state.

replysharereportpermalink
u/aleksi_eriksen6 points·9 days ago

amylin is not GLP-1, posts conflating them get corrected

replysharereportpermalink
u/anders_kuusela6 points·9 days ago

the half-life is incretin, affects steady state timing

replysharereportpermalink
u/rina_bergstrom5 points·8 days ago

Small correction: the trial was 13 weeks, not 26. Does not change your point but people will quote it.

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/glp1science
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/trialwatch_theou/gastric_emptying_gu/sig_figs_sam
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →